Merck nabs FDA blessing for Grastek immunotherapy; Akorn to sell 5 drugs for antitrust OK on Hi-Tech buyout; U.K. hep C charity calls Gilead drug unaffordable;

@FiercePharma: Top-read on FiercePharma Monday: New attention disorder could equal a big new ADHD drug market. But is it legit? Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: A Patheon (now DPx) plant that had been up for sale gets a $300M infusion to make Exparel for Pacira. Article | Follow @EricPFierce

@CarlyHFierce: J&J Q1 sales tally 18.1 billion... read more here. Release | Follow @CarlyHFierce

> Merck & Co. ($MRK) won FDA approval for its new, oral grass-pollen allergy immunotherapy, Grastek, hot on the heels of a similar rival from Stallergenes. Report

> Generics maker Akorn Enterprises ($AKRX) nabbed U.S. antitrust approval to buy rival Hi-Tech Pharmacal ($HITK), provided it sells off five of its copycat products. Report

> The U.K.'s Hepatitis C Trust called Gilead Sciences' ($GILD) new treatment for the disease cost-effective, but said it's not "affordable" for use by the country's National Health Service. Report

> Mylan ($MYL) and Prosonix teamed up to develop generic versions of GlaxoSmithKline's ($GSK) inhaled asthma drugs Flixotide and Flovent. Release

> Mylan ($MYL) and Actavis ($ACT) wrapped up a patent fight over Actavis' branded contraceptive Generess FE, in a deal that allows Mylan to launch its generic version in June 2015. Release

> Sanofi's ($SNY) Indian unit tapped N. Rajaram to head up its pharmaceuticals operations in the country. Report

Medical Device News

@FierceMedDev: Med tech VC Santé wraps up a $139M healthcare fund. Piece | Follow @FierceMedDev

@VarunSaxena2: Abbott's diabetes biz hit with its third Class I recall in a year. News | Follow @VarunSaxena2

@EmilyWFierce: Devices approved for pediatric use weren't tested in children first, new study finds. More | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story | Follow @MichaelGFierce

> TransEnterix raises $50M for surgical robot. Article

> Medtronic strikes back in its TAVR patent battle with Edwards. Story

Biotech News

@FierceBiotech: GlaxoSmithKline wins an FDA nod for its new #diabetes drug. More | Follow @FierceBiotech

@JohnCFierce: Little Lexicon posts positive diabetes data as rival pharma giants race ahead. Story | Follow @JohnCFierce

@DamianFierce: J&J's diagnostics business slipped another 7.1% on its way out the door. News | Follow @DamianFierce

@EmilyMFierce: New vaccine could guard against common birth defect-causing virus. Article | Follow @EmilyMFierce

> Merck bags FDA approval for its grass pollen pill Grastek. Story

> Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary. More

> Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy. Article

Biotech Research News

> Essential immune organ regenerated in mice. Story

> 3-D printed tumor mimics cancer better than 2-D model. Piece

> High protein levels linked to cell death in Parkinson's. More

> New vaccine could guard against common birth defect-causing virus. Article

> Plush 'carpets' of Silly Putty ingredient help stem cells grow. Feature

> UCSF rolls out patient database to boost brain research. Item

Pharma Manufacturing News

> Teva recalling more than 1M bottles of generic Cymbalta. Story

> FDA tags yet another Indian drugmaker, Canton Labs, with ban. More

> Plant that Patheon wanted to sell gets $300M investment. Article

> Impax believes manufacturing issues are fixed. News

> FDA bans Baxter plant that makes saline solution. Item

> ViiV recalls 1,000 bottles of Tivicay for cross-contamination. Report

And Finally... Doctors are prescribing opioid painkillers to pregnant women in large numbers, despite lack of proof that they are safe. Report